Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
KAI Pharmaceuticals
KAI Pharmaceuticals
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Parsabiv
Etelcalcetide
2017-02-07
2030-2034
Secondary hyperparathyroidism
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Etelcalcetide
hyperparathyroidism
,
secondary hyperparathyroidism
,
neoplasm metastasis
,
chronic kidney disease-mineral and bone disorder
,
chronic renal insufficiency
,
kidney diseases
,
bone diseases
Benzocaine
neoplasm metastasis
,
hyperparathyroidism
,
secondary hyperparathyroidism
,
chronic kidney disease-mineral and bone disorder
Ademetionine
neoplasm metastasis
,
hyperparathyroidism
,
secondary hyperparathyroidism
,
chronic kidney disease-mineral and bone disorder
DELCASERTIB
myocardial infarction
,
infarction
,
cardiovascular diseases
,
pathologic processes
Velcalcetide
hyperparathyroidism
,
secondary hyperparathyroidism
,
neoplasm metastasis
,
chronic kidney disease-mineral and bone disorder
,
chronic renal insufficiency
,
kidney diseases
,
bone diseases
Arm1
postoperative pain
Bolus
neoplasm metastasis
,
hyperparathyroidism
,
secondary hyperparathyroidism
,
chronic kidney disease-mineral and bone disorder
,
chronic renal insufficiency
,
kidney diseases
,
bone diseases
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use